Do analysts rate SILO or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Silo Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silo Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is CERO or SXTP more profitable?

CERo Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% 60 Degrees Pharmaceuticals -650.21% N/A -136.81%

Do analysts prefer JUNS or CERO?

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is JUNS or CERO more profitable?

CERo Therapeutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Jupiter Neurosciences N/A -1,314.62% -246.66% CERo Therapeutics N/A N/A -209.40%

Do analysts rate CERO or ORGS?

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CERo Therapeutics is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CERO or ORGS more profitable?

CERo Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Orgenesis -3,827.81% N/A -130.18%

Which has better valuation and earnings, CERO or SPRC?

CERo Therapeutics has higher earnings, but lower revenue than SciSparc. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CERo Therapeutics N/A N/A -$8.30M -$9.84 N/A SciSparc $860K 3.45 -$12.18M N/A N/A

Is CERO or SPRC more profitable?

Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% SciSparc N/A N/A N/A

CERo Therapeutics (CERO) Competitors

$0.01 0.00 (-7.56%)

As of 09/25/2026 03:40 PM Eastern

Compare

CERO vs. SILO, SXTP, JUNS, ORGS, and SPRC

Should you buy CERo Therapeutics stock or one of its competitors? CERo Therapeutics's main competitors and comparable companies include Silo Pharma (SILO), 60 Degrees Pharmaceuticals (SXTP), Jupiter Neurosciences (JUNS), Orgenesis (ORGS), and SciSparc (SPRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CERo Therapeutics compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Silo Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CERo Therapeutics has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. CERo Therapeutics' return on equity of 0.00% beat Silo Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, Silo Pharma had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for Silo Pharma and 0 mentions for CERo Therapeutics. Silo Pharma's average media sentiment score of 1.79 beat CERo Therapeutics' score of 0.00 indicating that Silo Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Silo Pharma	Very Positive
CERo Therapeutics	Neutral

CERo Therapeutics has a consensus price target of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CERo Therapeutics is more favorable than Silo Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Silo Pharma has higher revenue and earnings than CERo Therapeutics. Silo Pharma is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70K	39.75	-$4.23M	-$4.36	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

Summary

Silo Pharma beats CERo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

CERo Therapeutics (NASDAQ:CERO) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

CERo Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 272,627.27%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,083.76%. Given CERo Therapeutics' higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than 60 Degrees Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CERo Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than CERo Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
60 Degrees Pharmaceuticals	$1.41M	2.92	-$7.36M	-$4.82	N/A

CERo Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
60 Degrees Pharmaceuticals	-650.21%	N/A	-136.81%

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for CERo Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 1.33 beat CERo Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
60 Degrees Pharmaceuticals	Positive

Summary

60 Degrees Pharmaceuticals beats CERo Therapeutics on 10 of the 14 factors compared between the two stocks.

How does CERo Therapeutics compare to Jupiter Neurosciences?

Jupiter Neurosciences (NASDAQ:JUNS) and CERo Therapeutics (NASDAQ:CERO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Jupiter Neurosciences has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market. Comparatively, CERo Therapeutics has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market.

29.6% of CERo Therapeutics shares are owned by institutional investors. 38.6% of Jupiter Neurosciences shares are owned by insiders. Comparatively, 0.4% of CERo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CERo Therapeutics has lower revenue, but higher earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	121.49	-$8.65M	-$19.12	N/A
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

CERo Therapeutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-246.66%
CERo Therapeutics	N/A	N/A	-209.40%

In the previous week, Jupiter Neurosciences had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Jupiter Neurosciences and 0 mentions for CERo Therapeutics. Jupiter Neurosciences' average media sentiment score of 0.91 beat CERo Therapeutics' score of 0.00 indicating that Jupiter Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jupiter Neurosciences	Positive
CERo Therapeutics	Neutral

Summary

CERo Therapeutics beats Jupiter Neurosciences on 8 of the 13 factors compared between the two stocks.

How does CERo Therapeutics compare to Orgenesis?

CERo Therapeutics (NASDAQ:CERO) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

CERo Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market.

CERo Therapeutics has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
Orgenesis	$662K	3.90	-$55.36M	-$11.51	N/A

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, CERo Therapeutics' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Orgenesis	Neutral

CERo Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Orgenesis	-3,827.81%	N/A	-130.18%

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe CERo Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CERo Therapeutics beats Orgenesis on 7 of the 11 factors compared between the two stocks.

How does CERo Therapeutics compare to SciSparc?

CERo Therapeutics (NASDAQ:CERO) and SciSparc (NASDAQ:SPRC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

CERo Therapeutics has higher earnings, but lower revenue than SciSparc.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
SciSparc	$860K	3.45	-$12.18M	N/A	N/A

CERo Therapeutics has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, SciSparc has a beta of 2.81, meaning that its share price is 181% more volatile than the broader market.

In the previous week, SciSparc had 4 more articles in the media than CERo Therapeutics. MarketBeat recorded 4 mentions for SciSparc and 0 mentions for CERo Therapeutics. SciSparc's average media sentiment score of 0.68 beat CERo Therapeutics' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
SciSparc	Positive

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
SciSparc	N/A	N/A	N/A

CERo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 272,627.27%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
SciSparc	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 0.4% of CERo Therapeutics shares are owned by insiders. Comparatively, 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

SciSparc beats CERo Therapeutics on 6 of the 10 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERO vs. The Competition

Export

Metric	CERo Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$788K	$12.54B	$7.27B	$13.10B
Dividend Yield	N/A	2.63%	2.52%	13.51%
P/E Ratio	0.00	789.85	274.42	25.75
Price / Sales	N/A	748.37	618.37	86.14
Price / Cash	N/A	91.64	79.23	52.93
Price / Book	0.00	10.51	10.43	6.30
Net Income	-$8.30M	$2.81B	$3.49B	$359.77M
7 Day Performance	N/A	-0.96%	-1.25%	-0.23%
1 Month Performance	N/A	-3.00%	-4.67%	-3.88%
1 Year Performance	N/A	1.05%	15.06%	5.35%

CERo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERO CERo Therapeutics	0.6625 of 5 stars	$0.01 -7.6%	$30.00 +272,627.3%	-99.8%	$788K	N/A	N/A	8	News Coverage
SILO Silo Pharma	0.8843 of 5 stars	$1.94 -6.3%	N/A	-84.3%	$3.29M	$70K	N/A	2	Positive News Gap Up
SXTP 60 Degrees Pharmaceuticals	2.4126 of 5 stars	$0.85 -5.8%	$13.85 +1,536.3%	-79.0%	$3.16M	$1.41M	N/A	3	Positive News Gap Up
JUNS Jupiter Neurosciences	0.5419 of 5 stars	$3.01 -11.7%	N/A	-97.5%	$3.11M	$20K	N/A	5
ORGS Orgenesis	N/A	$0.67 +91.3%	N/A	+878.5%	$3.05M	$662K	N/A	150	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERO) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CERo Therapeutics (CERO) Competitors

CERO vs. SILO, SXTP, JUNS, ORGS, and SPRC

How does CERo Therapeutics compare to Silo Pharma?

Summary

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

How does CERo Therapeutics compare to Jupiter Neurosciences?

Summary

How does CERo Therapeutics compare to Orgenesis?

Summary

How does CERo Therapeutics compare to SciSparc?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CERo Therapeutics (CERO) Competitors

CERO vs. SILO, SXTP, JUNS, ORGS, and SPRC

How does CERo Therapeutics compare to Silo Pharma?

Which has more risk and volatility, SILO or CERO?

Do insiders and institutionals believe in SILO or CERO?

Is SILO or CERO more profitable?

Does the media refer more to SILO or CERO?

Do analysts rate SILO or CERO?

Which has better valuation & earnings, SILO or CERO?

Summary

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

Do analysts rate CERO or SXTP?

Do insiders & institutionals have more ownership in CERO or SXTP?

Which has more risk & volatility, CERO or SXTP?

Which has preferable earnings and valuation, CERO or SXTP?

Is CERO or SXTP more profitable?

Does the media favor CERO or SXTP?

Summary

How does CERo Therapeutics compare to Jupiter Neurosciences?

Which has more volatility & risk, JUNS or CERO?

Do institutionals & insiders believe in JUNS or CERO?

Which has preferable valuation & earnings, JUNS or CERO?

Do analysts prefer JUNS or CERO?

Is JUNS or CERO more profitable?

Does the media prefer JUNS or CERO?

Summary

How does CERo Therapeutics compare to Orgenesis?

Which has more volatility & risk, CERO or ORGS?

Which has higher valuation & earnings, CERO or ORGS?

Do insiders & institutionals believe in CERO or ORGS?

Does the media prefer CERO or ORGS?

Is CERO or ORGS more profitable?

Do analysts rate CERO or ORGS?

Summary

How does CERo Therapeutics compare to SciSparc?

Which has better valuation and earnings, CERO or SPRC?

Which has more risk & volatility, CERO or SPRC?

Does the media favor CERO or SPRC?

Is CERO or SPRC more profitable?

Do analysts rate CERO or SPRC?

Do institutionals & insiders believe in CERO or SPRC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERO vs. The Competition

CERo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools